Literature DB >> 7341279

The effects of erythromycin on the absorption and disposition of kinetics of theophylline.

T A Branigan, R A Robbins, W J Cady, J G Nickols, C T Ueda.   

Abstract

The effects of erythromycin on the kinetics of theophylline were investigated in eight female patients with documented asthma in a crossover study. Theophylline pharmacokinetics were determined at steady state before and after one-week treatment with erythromycin stearate 250 mg given four times a day. Multiple serum samples were collected for 12 h after an aminophylline dose in the two drug treatment phases and assayed by high performance liquid chromatography. The resultant serum theophylline concentration-time data were analyzed by weighted, nonlinear regression analysis to obtain various pharmacokinetic parameters. In this study, the elimination half-live increased from 7.8 +/- 1.7 h on the control day to 9.5 +/- 1.4 h following treatment with antibiotic (p less than 0.02). The estimated apparent volume of distribution for theophylline (V/F) was also observed to increase from 0.42 +/- 0.09 l/kg before treatment with erythromycin to 0.53 +/- 0.15 l/kg after antibiotic treatment (0.05 less than p less than 0.10). In this study, no difference was demonstrated in the apparent clearance rate (Clapp), apparent first-order absorption rate constant (ka), maximum serum drug concentration (Cmax), time of maximum drug concentration (Tmax) or absorption lag time (tlag) for theophylline before and after treatment with erythromycin. With no apparent alteration in theophylline clearance following erythromycin coadministration, the decrease in the first-order elimination rate constant suggested that the apparent volume of distribution of theophylline is increased in the presence of erythromycin. It is concluded that patients maintained on theophylline derivatives should be closely monitored when erythromycin is coadministered.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7341279     DOI: 10.1007/bf00637511

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Influence of diet and fluid on bioavailability of theophylline.

Authors:  P G Welling; L L Lyons; W A Craig; G A Trochta
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

2.  Influence of formulation on bioavailability of theophylline.

Authors:  P G Welling; J Domoradzki; J A Sims; C E Reed
Journal:  J Clin Pharmacol       Date:  1976-01       Impact factor: 3.126

3.  A rapid and sensitive method for determination of theophylline in plasma and saliva by high pressure liquid chromatography.

Authors:  G W Peng; V Smith; A Peng; W L Chiou
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-10

4.  Administration of erythromycin to patients on theophylline.

Authors:  P P Kozak; L H Cummins; S H Gillman
Journal:  J Allergy Clin Immunol       Date:  1977-08       Impact factor: 10.793

5.  Inhibition of theophylline clearance by troleandomycin.

Authors:  M Weinberger; D Hudgel; S Spector; C Chidsey
Journal:  J Allergy Clin Immunol       Date:  1977-03       Impact factor: 10.793

6.  Lack of effect of intravenous erythromycin lactobionate on theophylline clearance.

Authors:  B J Kimelblatt; R L Slaughter
Journal:  J Allergy Clin Immunol       Date:  1980-04       Impact factor: 10.793

7.  Pharmacokinetics and relative bioavailability of oral theophylline capsules.

Authors:  L J Lesko; A T Canada; G Eastwood; D Walker; D R Brousseau
Journal:  J Pharm Sci       Date:  1979-11       Impact factor: 3.534

8.  Effects of three antibiotics on theophylline kinetics.

Authors:  H J Pfeifer; D J Greenblatt; P Friedman
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

9.  Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms.

Authors:  D D Shen; M Fixley; D L Azarnoff
Journal:  J Pharm Sci       Date:  1978-07       Impact factor: 3.534

  9 in total
  11 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Effect of zileuton on theophylline pharmacokinetics.

Authors:  G R Granneman; R A Braeckman; C S Locke; J H Cavanaugh; L M Dubé; W M Awni
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

3.  Pharmacokinetic interaction between theophylline and erythromycin.

Authors:  A Iliopoulou; M E Aldhous; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 6.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

7.  Lack of clinically important interaction between erythromycin and theophylline.

Authors:  R Hildebrandt; U Gundert-Remy; H Möller; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Individualizing theophylline dosage: evaluation of a single-point maintenance dose prediction method.

Authors:  J H Wilkens; H Neuenkirchen; G W Sybrecht; M Oellerich
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 10.  Pharmacokinetic interactions of the macrolide antibiotics.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.